Mexilitene, a class 1b antiarrhythmic, was used throughout an entire pregnancy to treat symptomatic premature ventricular contractions in a patient with mitral valve prolapse. Cord blood and maternal serum mexilitene levels at the time of delivery are given. The following conclusions were reached. (1) Mexilitene may have a future in treating pregnant patients with arrhythmias unresponsive to currently approved antiarrhythmic drugs. (2) Evidence to date has shown no adverse affects in infants of mothers breast-feeding while taking mexilitene. (3) Dosages need to be monitored carefully during pregnancy and the postpartum period to ensure that therapeutic drug levels are maintained.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of perinatology : official journal of the California Perinatal Association|
|Publication status||Published - Dec 1 1988|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Obstetrics and Gynecology